News Releases
New COPD Rx Lands FDA Approval
EAST HANOVER, N.J., Oct. 29, 2015 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved the dual combination bronchodilator Utibron™ Neohaler® (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.
New COPD Treatment Approved
Ingelheim, Germany, 21. May 2015 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat® (tiotropium bromide and olodaterol) Inhalation Spray.
New Cystic Fibrosis Rx Shows Promise
Today an advisory committee of the U.S. Food and Drug Administration (FDA) voted 12 to 1 to recommend that the FDA approve the potential ivacaftor/lumacaftor combination drug (Orkambi).
Spiriva Respimat Inhalation Spray Now Available in the United States
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray is now available by prescription through retail pharmacies across the United States.
FDA Approves New Asthma Inhaler with Dose Counter
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the use of QVAR® (beclomethasone dipropionate HFA) with a dose counter for the ongoing treatment of asthma as a preventative therapy in patients 5 years of age and older.
FDA Approves New COPD Treatment
The FDA has approved a new treatment to help COPD patients breathe easier.
FDA Approves New Inhaler for COPD
The FDA has approved a new inhaler for patients with chronic obstructive pulmonary disease (COPD).
FDA Advisory Committee Recommends Approval in US of Umeclidinium/Vilanterol
GlaxoSmithKline plc and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted 11 yes to 2 no that the efficacy and safety data provide substantial evidence to support approval of umeclidinium/vilanterol (UMEC/VI, 62.5/25 mcg dose) for the long-term, once-daily, maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Better News for Patient on Ventilation
New clinical guidelines for use of noninvasive ventilation in critical care settings are published in the Canadian Medical Association Journal.
A Plan to Help the Pre-existing Condition Crowd
The U.S. Department of Health and Human Services (HHS) is increasing awareness about a health plan for uninsured Americans with pre-existing conditions created by the Affordable Care Act.